Vaccine stocks conclude 2025 with losses, with Pfizer (PFE.N) , Moderna (MRNA.O) , Novavax (NVAX.O) and BioNTech (22UAy.DE) (BNTX.O) all in red
U.S. vaccines have been under pressure since vaccine-skeptic Robert F. Kennedy Jr. became health secretary and has worked to reduce the country’s reliance on the interventions
Shares of Pfizer have fallen 5.8% this year; shares of the company have dropped more than 50% since early 2023 as demand for COVID-19 vaccines and treatments waned
Shares of Moderna are down 26.9% this year, on track for a fourth straight year of losses
Kennedy, a longtime vaccine skeptic, has made far-reaching changes to the U.S. vaccine policy, which include dropping a long-standing recommendation for the hepatitis B birth dose, cutting funding for mRNA vaccines and, contrary to established science, linking vaccines to autism
Shares of Novavax have fallen 16.4% this year after rising 67.5% in 2024; the company pushed back its profitability target by a year to 2028
U.S. listed shares of BioNTech are down 16.4% this year after rising about 8% in 2024
Vaccine makers end year in losses
<img src="https://imageproxy.pbkrs.com/https://tmsnrt.rs/493snak?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="960" height="720" original-src="https://imageproxy.pbkrs.com/https://tmsnrt.rs/493snak"/>

MRNA

BNTX

NVAX

Vaccine stocks, including Pfizer, Moderna, Novavax, and BioNTech, ended 2025 with significant losses. Pfizer's shares fell 5.8% this year, dropping over 50% since early 2023 due to decreased demand for COVID-19 vaccines. Moderna's shares are down 26.9%, marking a fourth consecutive year of losses. Novavax and BioNTech also saw declines of 16.4%. The downturn is attributed to changes in U.S. vaccine policy under health secretary Robert F. Kennedy Jr., who has implemented measures that have negatively impacted vaccine reliance and funding.

- Vaccine stocks, including Pfizer, Moderna, Novavax, and BioNTech, experienced significant losses in 2025.  
- U.S. vaccines have faced challenges since Robert F. Kennedy Jr. became health secretary, implementing policies that reduced reliance on vaccines and funding for mRNA vaccines.  
- As a result, shares for these companies have seen steep declines, with Pfizer's shares down over 50% since early 2023 and Moderna on track for a fourth consecutive year of losses.

BUZZ-Vaccine makers end the year in red